IL22 and graft versus host disease: IL-6 is an important cytokine for the development of the Th17 immune response, when IL-22 is expressed by these cells.[19] We may conclude that MSCs are more effective at treating GvHD, when the disease's characteristics are low levels of the Th17 immune response.